NEWARK, Calif., Sept. 1, 2016 /PRNewswire/ -- DNA2.0 Inc., a pioneer in bioengineering solutions, today announced the issuance of a patent by the U.S. Patent and Trademark Office (USPTO) for LeapIn, the company's innovative transposon- and transposase-based tool. Patent No. 9,428,767 entitled "Enhanced nucleic acid constructs for eukaryotic gene expression," covers configurations of vectors for improved heterologous gene expression, methods for identifying these configurations and the use of transposons and transposases.
"Our transposon-, and transposase-based tools have applications in gene expression, gene therapy and gene discovery," said Kate Caves, director of business development and marketing at DNA2.0 and a biologist who was one of the inventors. "We have already seen strong interest from protein pharmaceutical companies in our proprietary tools for transient and stable protein production in mammalian hosts. Now more than ever, we are in a position to apply our bioengineering tools to the entire spectrum of scale, from building better genes, proteins and pathways all the way to genomes."
"This is the first of our genome modification patents to issue," said Jeremy Minshull, PhD, CEO of DNA2.0. "We are committed to building a recombinant protein expression platform in combination with our operational focus on our new state-of-the-art mammalian protein production laboratory, and our recent acquisition of antibody production company Migs. These are all underpinned by our technology base of machine learning and industrial scale gene synthesis."
DNA2.0 has 16 patents in the U.S.
DNA2.0 is the leading bioengineering solutions provider, offering an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering and production. DNA2.0 explores novel applications for synthetic genes and the synergy between efficient gene design and protein optimization technologies. DNA2.0's tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Newark, California. For more information, please visit http://www.DNA20.com.
Lisa Lilienthal, 404.661.3679
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dna20-leapin-transposons-protected-by-newly-issued-us-patent-300321351.html
SOURCE DNA2.0 Inc.